Lung cancer is now the most common malignancy in men world-wide and is expected to overtake breast cancer as the leading cause of mortality in women. Small cell lung cancer (SCLC), which accounts for about 25% of new cases, differs from other lung neoplasms in two important respects. Firstly, SCLC is highly metastatic. Most patients present with mediastinal metastases, extrathoracic metastases, or both. Secondly, SCLC is highly chemoresponsive. Combination chemotherapy results in high remission rates but most patients die of their disease within two years following the development of drug resistance and few patients achieve long-term survival. There is a clear need, therefore, to investigate cytotoxic agents which act by a different mechanism from the agents in current use and which can be administered systemically. A novel approach is the use of monoclonal antibodies to deliver toxic proteins, such as the ribosomeinactivating protein ricin A chain, to sites of tumour. Antibody-toxin conjugates, or immunotoxins (ITs), made with monoclonal antibodies recognising tumour-associated antigens have demonstrated selective toxic effects against human tumour cells in tissue culture and in animal models of cancer, and are currently undergoing clinical trials in patients (Blakey et al., 1988) .
The First International Workshop on SCLC Antigens identified several different groups, or clusters, of monoclonal antibodies that recognise discrete cell-surface antigens associated with SCLC. Each cluster of antibodies displayed a characteristic spectrum of binding to normal and malignant tissues and cell lines of pulmonary, neuroendocrine and epithelial origin (Souhami et al., 1988) . A number of monoclonal antibodies making up clusters designated w4 and 5A have been described previously . SWA1 1, which is associated with cluster w4, shows strong reactivity with both classic and variant SCLC cell lines in vitro. This antibody localises efficiently in human SCLC tumour xenografts in vivo (Smith et al., 1989) and inhibits tumour growth when conjugated to '3'I (Smith et al., 1990) . SWA20, belonging to cluster SA, recognises a sialoglycoprotein antigen expressed selectively by a proportion of SCLC cell lines and primary SCLC tumours Maier et al., 1989) .
In this study, we have assessed the potential of the anti-SCLC antibodies to form cytotoxic agents with ricin A chain by using a modified version of the indirect in vitro screening procedure developed by Weltman et al. (1987) and Till et al. (1988) . When the human classic SCLC cell line HC12 was exposed to the SWA 11 antibody and then incubated with the screening agent, sheep anti-mouse IgG Fab' fragment linked to ricin A chain (SAMIgG Fab'-ricin A chain), cellular protein synthesis was inhibited in dose-dependent fashion. An IT made by the direct chemical conjugation of ricin A chain to the SWAl1 antibody displayed selective toxic effects upon the HC12 cell line, confirming the prediction of the indirect assay.
Materials and methods

Materials
Castor bean cake derived from the seeds of Ricinus communis of Sri Lankan origin was a gift of Croda Premier Oils, Hull, Humberside, England. The anti-SCLC mouse monoclonal antibodies, SWAl 1 and SWA20, were purified from hybridoma supernatants as described by Smith et al. (1989) . The control mouse monoclonal antibody raised against vesicular stomatitis virus, 2AL-1, was purified from ascitic fluid (Forrester et al., 1984) . All three antibodies are of the IgG2a subclass. The human classic SCLC cell line HC12 (Duchesne et al., 1987) was the gift of Dr. G. Duchesne, Institute of Cancer Research, Sutton. The human classic SCLC cell line NCI-H69 and the human lung adenocarcinoma cell line NCIIgG F(ab')2 fragment (M-1522), dithiothreitol (DTT), ophenylenediamine and thimerosal were from Sigma Chemical Co. Ltd., Poole, Dorset, England. N-iodoacetyl-Nbiotinylhexylenediamine (iodoacetyl-LC-biotin) was from Pierce & Warriner (UK) Ltd., Chester, Cheshire, England. 5,5'-dithiobis (2-nitrobenzoic acid) (Ellman's reagent) was purchased from Aldrich Chemical Co. Ltd., Gillingham, Dorset, England. Casein (hammersten grade) was obtained from BDH Ltd., Poole, Dorset, England. All other reagents were of the highest available purity.
Preparation of immunotoxins:
Purification of ricin A chain Ricin was isolated from an aqueous extract of defatted castor bean cake using the methods described by Cumber et al. (1985) . Ricin A chain was isolated from the toxin by reductive cleavage and further purified using immobilised asialofetuin as described by Forrester et al. (1984) .
Preparation of immunotoxins with mouse monoclonal antibodies Ricin A chain was attached to the SWAl1 and SWA20 monoclonal antibodies via a disulphide bond using procedures described in detail by Cumber et al. (1985 (Forrester et al., 1984 41 of 20 mM sodium phosphate buffer containing 0.14 M NaCl, I mM EDTA, pH 6.5 at 4°C . To 7 ml of the solution containing about 5 mg of Fab' substituted with Ellman's reagent was added 7 ml of a solution containing 7.5 mg ricin A chain in 20 mM sodium phosphate buffer containing 0.14 M NaCI, I mM EDTA, pH 7.5 (PE buffer).
The reaction mixture was left overnight at room temperature, then concentrated to about 8 ml by ultrafiltration using an Amicon PM10 membrane and subjected to gel permeation chromatography on a column (90 cm x 1.6 cm diameter) of Sephacryl S200 (HR) equilibrated with PE buffer. The pooled fraction corresponding to Fab'-ricin A chain (Mr, approximately 80,000) was concentrated to about 4 ml by ultrafiltration, dialysed into 50 mM sodium phosphate buffer, pH 7.5, and applied to a column (17 cm x 1.2 cm diameter) of Blue Sepharose CL-6B equilibrated with the same buffer. The Fab'-ricin A chain eluted from the column with 50 mM sodium phosphate buffer containing 0.5 M NaCl, pH 7.5, and was judged by SDS-PAGE to be essentially free from contamination by free ricin A chain and unconjugated antibody fragments. The product was sterilised by filtration and stored at 4°C. SAMIgG Fab'-LC-biotin bound to immobilised mouse antibody was detected using a streptavidin-biotinylated HRP complex. As shown in Figure 1 , there was no significant difference between the binding curves for the three monoclonal antibodies, indicating that the Fab' fragment bound similarly to each antibody. In the indirect assay of IT cytotoxicity, HC12 cells were first treated with a single concentration of each of the three monoclonal antibodies. The cells were then washed and incubated with the screening agent, SAMIgG Fab'-ricin A chain, at various concentrations. Figure 2 shows the effects of these treatments on cellular protein synthesis. The incorporation of [3H] leucine was greatly reduced in cells treated with SWA 1 followed by the screening agent, compared with cells in control cultures incubated with the screening agent alone. This cytotoxic effect was dose-dependent; protein synthesis was inhibited by 75% at a SAMIgG Fab'-ricin A chain concentration of I x 10-iM and by 94% at the 10-fold higher concentration of the screening agent. The inhibition of protein synthesis was dependent upon the presence of the screening agent because cells exposed to the SWA1 1 antibody alone were not affected. Protein synthesis in HC12 cells treated with SWA20 in combination with the screening agent was also inhibited in a dose-dependent manner. However, the effect was much weaker than that observed with SWAl (Figure 4 and Table I ). SWAl 1-ricin A chain inhibited protein synthesis with an IC50 of about 6 x 101 M. This concentration was about 10-fold lower than that observed when the cells were exposed to the IT for only 1 h before incubation (Figure 3) indicating that continuous exposure led to a higher uptake of the IT by the cells. SWA20-ricin A chain demonstrated a substantially less potent cytotoxic effect: its IC_, was about 2 x 10-8 M, that is, more than 30-fold higher than the IC50 for SWAl 1-ricin A chain (Figure 4 ) in accordance with the predictions of the indirect assay of IT cytotoxicity. The SWA 11 and SWA20 ITs were both appreciably less toxic to the HC12 cell line than ricin toxin itself which had an IC5) of about 5 x 10-'s M (Figure 4) . At the highest concentration tested, that is, at I X 10-7 M, SWA1 l-ricin A chain inhibited protein synthesis by 98% (Figure 4) . At the same concentration, the isotypematched control IT, 2AL-1-ricin A chain, inhibited protein synthesis by less than 15% (Figure 4) showing that the cytotoxic effects observed in the presence of SWAll-ricin A chain were not due to antigen-independent uptake of IT by the cells. The observed cytotoxic effects of the SWAl IT were dependent upon the covalent combination of the two components of the conjugate. The SWA 11 antibody alone at a concentration of I x 10-7 M, ricin A chain alone at a concentration of I x 10-7 M, or a simple mixture of antibody and A chain at the same concentrations had no effect on protein synthesis by HC12 cells (not shown). Figure 3 Cytotoxic effects of SWAJI-ricin A chain compared with SWAl1-mediated cytotoxicity in the indirect assay. HC12 cells were exposed either to SWA1 -ricin A chain at various concentrations between I x 10-`0M and I x 10-7M for 1 h followed by incubation in assay medium for 47 h (0), or to SWAI I at the same concentrations for I h followed by incubation in the presence of SAMIgG Fab'-ricin A chain at 1 x 10' M for 47 h (0). The The ability of SWA 1 1-ricin A chain to exert cytotoxic effects against other human lung tumour cell lines was tested using two cell lines, NCI-H69, a classic SCLC cell line expressing the antigen recognised by SWA 11, and, NCI-H23, a lung adenocarcinoma cell line found not to bind SWAl 1 by indirect immunofluorescence analysis. SWAll-ricin A chain inhibited the incorporation of [3H] leucine by NCI-H69 cells upon continuous incubation in tissue culture with an IC50 of about 4 x 10-10 M (Table I ) comparable with its potency against the HC12 cell line. Ricin was a more potent cytotoxic agent than SWAl 1-ricin A chain against both SCLC cell lines; the IC50 for ricin was 1,400-fold less than that of the IT in the case of the HC12 cell line and about 370-fold less in the case of the NCI-H69 cell line. 2AL-1-ricin A chain exerted no significant cytotoxic effects against either cell line at a concentration of 5 x 10-8 M. In contrast to the effects observed against the two SCLC cell lines, SWAl 1-ricin A chain had no significant cytotoxic effects upon the non-SCLC cell line NCI-H23 at a concentration of 1 x 10-8 M. Moreover, the SWA 11 IT at the same concentration was unable to inhibit protein synthesis by a human non-lung tumour cell line, the EJ bladder carcinoma cell line (not shown).
I.I Discussion
In this study, we have shown that an indirect screening procedure accurately predicted the cytotoxic potency of ITs made by linking ricin A chain to the SWAl 1 and SWA20 monoclonal antibodies against the human classic SCLC cell line HC12 in tissue culture. The principle of indirect screening of antibody-mediated delivery of toxin to target cells was introduced by Weltman et al. (1986 Weltman et al. ( , 1987 to enable the analysis of hybridoma ascites and supernatants for the presence of monoclonal antibodies that were likely to form ITs with cytotoxic activity. The approach was validated by Till et al. (1988) using a goat anti-mouse Ig Fab-ricin A chain conjugate; there was good correlation between the cytotoxic effects of a large panel of monoclonal antibodies directed against lymphoid cells in the indirect assay and the toxicity of the corresponding ITs made with these antibodies to lymphoid cell lines. The assay we describe, using SAMIgG Fab'-ricin A chain, will enable existing and novel monoclonal antibodies recognising different antigens associated with SCLC and other lung neoplasms to be screened for their suitability to make ITs with therapeutic potential. SWA1 l-ricin A chain is the most potent IT against human SCLC yet described and is the first reported IT that recognises a defined SCLC-associated antigen designated the cluster w4 antigen by the First International Workshop on SCLC Antigens (Souhami et al., 1988) . There is one previous report of an antibody-toxin conjugate directed against human SCLC. Weltman et al. (1987) raised hybridoma cell lines by immtnising animals with the human classic SCLC cell line NCI-H69, screened supernatants by the indirect method, and identified a monoclonal antibody that was a candidate for IT synthesis. An IT constructed from this antibody and the ribosome-inactivating protein pokeweed antiviral protein (PAP), was cytotoxic to the NCI-H69 cell line in tissue culture with an ICso of approximately 2 X IO-9 M. These cytotoxicity experiments were conducted in the presence of 0.1 M chloroquine, an agent which has been shown to be capable of enhancing the cytotoxic potency of ITs containing PAP (Ramakrishnan & Houston, 1984) . In contrast, we have shown that SWA11-ricin A chain was an effective and selective cytotoxic agent against two human SCLC cell lines, HC12 and NCI-H69, in the absence of any potentiating agent. The lower cytotoxic potency of SWA20-ricin A chain against the HC12 cell line, compared to that of the SWAl 1 IT, may have been a consequence of the lower level of binding of the SWA20 antibody to the cells compared with the binding of SWAl1. Human SCLC cell lines expressing higher levels of the cluster 5A antigen could prove more susceptible to the action of the SWA20 IT.
SWAlI-ricin A chain was about 370-to 1,400-fold less toxic to the SCLC target cell lines than ricin, indicating that the entry of the A chain into the cytosol by the antigenmediated route was much less efficient than entry via the route followed by the intact toxin. It is possible that the potency of the SWA 11 IT could be potentiated by the use of agents which are capable of altering the intracellular fate of internalised IT such as the lysosomotropic agents chloroquine or ammonium chloride. An alternative approach is suggested by the studies of Press et al. (1988) who demonstrated that the potency of ricin A chain ITs directed against the lymphocyte CD2 antigen depended upon the epitope recognised by the CD2 monoclonal antibody. Thus, monoclonal antibodies to the cluster w4 antigen that recognise epitopes different from those recognised by SWAl1 could form ricin A chain ITs with higher cytotoxic potency against SCLC cells than the IT made with SWAl 1.
Studies with the SWAl1 antibody have previously shown that it has a high avidity of binding for its target antigen and that it localises effectively in vivo in a human SCLC tumour xenograft growing in nude mice (Smith et al., 1989) . Further studies will be directed towards determining the possible value of ITs made with SWA 11 and with other monoclonal antibodies recognising the cluster w4 antigen as therapeutic agents by determining their ability to inhibit the growth of human SCLC xenografts in experimental animals.
